摘要
背景:引起神经原纤维缠结并最终导致细胞死亡的淀粉样蛋白(AB)毒性链的积累被怀疑是阿尔茨海默氏病临床症状的主要罪魁祸首。尽管由于AB积累引起的细胞死亡的机制是众所周知的,但是在积累开始和细胞死亡之间的中间阶段却鲜为人知和研究,部分是由于鉴定部分受影响的细胞方面的技术挑战。目的:首先,我们旨在建立一个体外模型,该模型可显示出抗AB毒性的能力。然后,我们使用形态学,分子学和电生理学方法研究了AB毒性后存活细胞的特征如何变化。 方法:为了研究这一阶段,我们利用视黄酸(RA)和脑源性神经营养因子(BDNF)分化了SH-SY5Y神经母细胞瘤干细胞,建立了一个能够证明对AB毒性具有不同水平抗药性的体外模型。 。我们利用荧光显微镜和全细胞膜片钳记录来研究模型的行为。 结果:与仅视黄酸相比,我们观察到在由视黄酸和脑源性神经营养因子分化的细胞中,对AB毒性的形态学复原力显着更高。然而,在AB处理后,维甲酸+脑源性神经营养因子分化的细胞的电生理特性发生了明显变化。结论:我们建立了AB毒性的瞬时存活模型,并观察了AB对分化神经元跨膜电流的影响。
关键词: SH-SY5Y细胞系,膜片钳,视黄酸,脑源性神经营养因子,β淀粉样蛋白毒性,细胞培养。
Current Alzheimer Research
Title:A Transient Survival Model of Alteration of Electrophysiological Properties Due to Amyloid Beta Toxicity Based on SH-SY5Y Cell Line
Volume: 17 Issue: 13
关键词: SH-SY5Y细胞系,膜片钳,视黄酸,脑源性神经营养因子,β淀粉样蛋白毒性,细胞培养。
摘要:
Background: Accumulation of toxic strands of amyloid beta (AB), which cause neurofibrillary tangles and, ultimately, cell death, is suspected to be the main culprit behind clinical symptoms of Alzheimer’s disease. Although the mechanism of cell death due to AB accumulation is well known, the intermediate phase between the start of accumulation and cell death is less known and investigated, partially due to technical challenges in identifying partially affected cells.
Objective: First, we aimed to establish an in vitro model that would show resilience against AB toxicity. Then we used morphological, molecular and electrophysiological assays to investigate how the characteristics of the surviving cells changed after AB toxicity.
Methods: To investigate this phase, we used differentiation of SH-SY5Y neuroblastoma stem cells by Retinoic Acid (RA) and Brain Derived Neurotrophic Factor (BDNF) to establish an in vitro model which would be able to demonstrate various levels of resistance to AB toxicity. We utilized fluorescent microscopy and whole cell patch clamp recordings to investigate behavior of the model.
Results: We observed significantly higher morphological resilience against AB toxicity in cells which were differentiated by both Retinoic Acid and Brain Derived Neurotrophic Factor compared to Retinoic Acid only. However, the electrophysiological properties of the Retinoic Acid + Brain-Derived Neurotrophic Factor differentiated cells were significantly altered after AB treatment.
Conclusion: We established a transient survival model for AB toxicity and observed the effects of AB on transmembrane currents of differentiated neurons.
Export Options
About this article
Cite this article as:
A Transient Survival Model of Alteration of Electrophysiological Properties Due to Amyloid Beta Toxicity Based on SH-SY5Y Cell Line, Current Alzheimer Research 2020; 17 (13) . https://dx.doi.org/10.2174/1567205018666210212155750
DOI https://dx.doi.org/10.2174/1567205018666210212155750 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Present and Potential Industrial Applications of Macro- and Microalgae
Recent Patents on Food, Nutrition & Agriculture The Mitochondrial Dynamics of Alzheimers Disease and Parkinsons Disease Offer Important Opportunities for Therapeutic Intervention
Current Pharmaceutical Design Phytometabolites Targeting the Warburg Effect in Cancer Cells: A Mechanistic Review
Current Drug Targets Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy
Current Pharmaceutical Biotechnology A Review on Chitosan in Drug Delivery for Treatment of Neurological and Psychiatric Disorders
Current Pharmaceutical Biotechnology 7-aa Peptide Mimic from HVR1 of HCV Protects Hepatic Injury in Rats by Reduced Expression of Key Pro-Inflammatory Factors
Inflammation & Allergy - Drug Targets (Discontinued) CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets Pharmacology of Sigma (σ) Receptor Ligands from a Behavioral Perspective
Current Pharmaceutical Design Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimers Disease Pyramidal Neurons
Current Pharmaceutical Design Ion Channel Screening Technology
CNS & Neurological Disorders - Drug Targets Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine